Description

Butyl 4-(4-(tert-Butoxycarbonyl)Piperazin-1-Yl)-6,8-Difluoroquinoline-2-Carboxylate CAS NO 1130309-31-7 is a high-purity, advanced pharmaceutical intermediate featuring a complex quinoline-piperazine hybrid structure. This compound is critical for medicinal chemistry research and development, particularly in the synthesis of novel active pharmaceutical ingredients (APIs). It is primarily utilized by pharmaceutical R&D laboratories and fine chemical manufacturers focused on developing new therapeutic agents, especially in the areas of oncology and anti-infectives.

Application

• Key Intermediate in Pharmaceutical Synthesis: Serves as a crucial building block for the development of novel quinoline-based drug candidates.
• Medicinal Chemistry Research: Used in structure-activity relationship (SAR) studies to optimize biological activity and pharmacokinetic properties.
• API Development: Integral in the synthetic route for potential Active Pharmaceutical Ingredients (APIs), particularly for anticancer and antimicrobial applications.
• Custom Synthesis & Contract Manufacturing: Supplied to CDMOs (Contract Development and Manufacturing Organizations) for scale-up and process development.
• Academic & Institutional Research: Utilized in university and institutional labs for exploratory drug discovery projects.
• Pre-clinical Candidate Development: Employed in the synthesis of compounds for pre-clinical toxicology and efficacy studies.

Basic Information

Product Name	Butyl 4-(4-(tert-Butoxycarbonyl)Piperazin-1-Yl)-6,8-Difluoroquinoline-2-Carboxylate
CAS No.	1130309-31-7
Molecular Formula	C23H29F2N3O4
Molecular Weight	449.49 g/mol
Synonyms	Butyl 4-[4-(tert-butoxycarbonyl)piperazin-1-yl]-6,8-difluoroquinoline-2-carboxylate; 6,8-Difluoro-4-[4-(tert-butoxycarbonyl)-1-piperazinyl]-2-quinolinecarboxylic Acid Butyl Ester; 2-Quinolinecarboxylic acid, 6,8-difluoro-4-[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]-, butyl ester; tert-Butyl 4-(6,8-difluoro-2-(butoxycarbonyl)quinolin-4-yl)piperazine-1-carboxylate; BOC-Piperazine-Quinoline Derivative; 1130309-31-7
EINECS	Contact for details

Quality Control

Our Butyl 4-(4-(tert-Butoxycarbonyl)Piperazin-1-Yl)-6,8-Difluoroquinoline-2-Carboxylate is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing, including HPLC, NMR, and MS, to ensure identity, purity, and consistency. We provide comprehensive Certificates of Analysis (COA) with each shipment, detailing all critical specifications. Our quality commitment aligns with cGMP principles for pharmaceutical intermediates, ensuring reliability for your critical R&D and scale-up processes.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). The compound is sensitive to strong acids and organic solvents; ensure storage areas are well-ventilated and segregated from incompatible materials. For long-term storage, consider inert atmosphere conditions to maximize stability.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 10 ppm
Single Unknown Impurity (HPLC)	≤ 0.5%
Total Impurities (HPLC)	≤ 2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.